Physician profile
Gerri Dyer
NPI 1952328486
$5,696.01
in general payments reported to CMS, 2019-2025
22 companies · $1,199 in 2025
The $1,199 reported for 2025 was more than what 88% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $889 · 2022: $714 · 2023: $1,560 · 2024: $1,334 · 2025: $1,199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,821 · Education: $272.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,820.61 |
| Education | $272.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $939.34 | 2021-2025 | Otezla, Otezla |
| Abbvie INC. | $596.25 | 2021-2025 | |
| Incyte Corporation | $531.02 | 2022-2025 | Opzelura, Opzelura |
| E.R. Squibb & Sons, L.L.C. | $512.36 | 2022-2024 | Sotyktu |
| Janssen Biotech, INC. | $408.59 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Pfizer INC. | $394.18 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $366.89 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $301.01 | 2021-2024 | Ilumya |
| Ucb, INC. | $243.30 | 2021-2025 | Bimzelx |
| Galderma Laboratories, L.P. | $235.80 | 2021-2025 | Nemluvio |
| Genzyme Corporation | $219.42 | 2022-2025 | |
| Strata Skin Sciences, INC. | $194.95 | 2023-2025 | Xtrac |
| Regeneron Healthcare Solutions, INC. | $183.58 | 2022-2025 | Libtayo |
| Leo Pharma INC. | $137.69 | 2021-2022 | |
| Lilly USA, LLC | $134.09 | 2022-2025 | Ebglyss, Taltz, Olumiant |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $85.38 | 2022-2023 | Vtama |
| Biofrontera INC. | $81.56 | 2022-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.95 | 2023-2025 | Spevigo |
| Arcutis Biotherapeutics, INC. | $30.00 | 2023 | |
| Organogenesis INC. | $20.92 | 2025 | Affinity |
| Genentech USA, INC. | $17.47 | 2022 | |
| Fresenius Kabi USA, LLC | $16.26 | 2023 | Idacio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerri Dyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.